Shares jumped 44% this week after the company reported its first full quarter after winning FDA approval for its T-cell melanoma therapy Amtavi (lifecel).

I start this week with a quote - “It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of light, it was the season of darkness, it was the spring of hope, it was the winter of despair.”

I have a simple cash skim for you today: HashiCorp (SYM: HCP) here at $32.50.

My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.

The biotech sector has sold off big time in the past 60 days, and Iovance (SYM: IOVA) has sold off along with it.

Back in the 90’s, Wall Street started putting pressure on Big Pharma to get better returns on their R&D spending.

Judging by all the emails we got over the weekend, most of you know Iovance Biotheutics (SYM: IOVA) won FDA approval for lifileucel.

Rumors of a takeover have surrounded Shockwave for years. This cardiovascular device maker would make a great fit for Johnson & Johnson, Medtronic or Boston Scientific.

I’m also thankful that I get to share some good news with you today regarding Iovance Biotherapeutics (SYM: IOVA).

I’ve been touting Iovance (SYM: IOVA) for so long, I may have to fall on my sword Japanese-style if it doesn’t work out.